On the basis of the therapy, the China Huntington’s disease therapeutics market is segmented into physical therapy and occupational therapy.
Physical therapy can help maintain mobility and prevent falls through tailored exercises for the patient. This can be complemented by occupational therapy that helps the patient establish coping strategies and identify ways to make his or her life easier, either through simple changes or the introduction of assistive devices.
By Drug Type:
On the basis of the drug type, the China Huntington’s disease therapeutics market is segmented into antipsychotics, antidepressants and anticonvulsants.
Antipsychotics consist of drugs such as Haloperidol and Quetiapine. Antidepressants includes Fluoxetine, Bupropion, Venlafaxine and Nefazodone. Anticonvulsant drug include Lamotrigine. These drugs are preferred for treatment for instance, Antidepressants, mainly selective serotonin reuptake inhibitors are frequently used to treat Huntington’s patients’ depression. They can also alleviate some symptoms of obsessive-compulsive disorder.
Antipsychotic medications can help manage psychiatric symptoms associated with Huntington’s disease, including agitation and psychosis.
By Distribution Channels:
Based on the distribution channels, China Huntington’s disease therapeutics market is segmented into hospitals, retail, online pharmacies. During the forecast period (2020-2028) retail pharmacies and online pharmacies will dominate the HAE therapeutics market due to easy accessibility, increase in preference for online pharmacies and discounted rate on medicines at these pharmacies. Hospital pharmacies are second largest distribution channels during the forecast period.
Some of the key players in the Huntington’s disease therapeutics market are Teva Pharmaceutical Industries Ltd; Neurocrine Biosciences Inc; Pfizer Inc; H. Lundbeck A/S.
Key players are adopting various strategies such as strategic collaboration, partnership and licensing agreement to increase their market share. For instance, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of valbenazine for movement disorders in China and other Asian countries.
In May 2020 Teva Pharmaceuticals’ Austedo (Deutetrabenazine tablets) has been approved by China’s National Medical Products Administration (NMPA) for treating Huntington’s disease.